Overview
What is Overton Brooks Research Corporation?
Overton Brooks Research Corporation is a nonprofit organization based in Shreveport, Louisiana, dedicated to supporting and facilitating medical research activities of its members in conjunction with the Overton Brooks Veterans Affairs Medical Center. The corporation plays a significant role in the National Institutes of Health (NIH) Study 2016-05, led by Dr. Philip Haddad, aiming to build diverse health databases by inviting individuals from across the USA. The goal is to enroll 40 participants monthly and collect their blood samples, ultimately assembling a comprehensive biomedical dataset to accelerate medical research breakthroughs. By collaborating with this study, Overton Brooks Research Corporation contributes to expediting the understanding of how various factors are linked to diseases or treatments, potentially speeding up the discovery process. The organization currently employs a team of six individuals.
Is Overton Brooks Research Corporation legitimate?
Overton Brooks Research Corporation is a legitimate nonprofit organization registered as a 501(c)(3) entity. Overton Brooks Research Corporation submitted a form 990, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.
Heare are some key statistics you may want to consider:
Executive Compensation: $760
Professional Fundraising Fees: $0
Other Salaries and Wages: $154,413
For more financial information, click here
What is the mission statement of Overton Brooks Research Corporation?
The Overton Brooks Research Corporation's primary objective is to support and facilitate medical research activities of its members in collaboration with the Overton Brooks Veterans Affairs Medical Center. The corporation aims to contribute to advancements in medical research by providing a conducive environment for its members. One of their initiatives involves participating in the All of Us study, led by the National Institutes of Health (NIH), with the goal of enrolling 40 individuals monthly for a diverse health database. This project aims to accelerate medical research breakthroughs by creating a vast biomedical dataset, potentially speeding up the understanding of how various factors are linked to diseases or treatments.
Who is the CEO of Overton Brooks Research Corporation?
John T Gleason is the Director of Overton Brooks Research Corporation.
What is the revenue of Overton Brooks Research Corporation?
Overton Brooks Research Corporation's revenue in 2023 was $264,258.
Who are the executives of Overton Brooks Research Corporation and what are their salaries?
The average compensation at Overton Brooks Research Corporation during 2023 was $25,862. There are 6 employees and 4 volunteers at Overton Brooks Research Corporation.
Here are 6 key members and their salaries:
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $520
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
Where can I find the form 990 for Overton Brooks Research Corporation?
Overton Brooks Research Corporation's most recent form 990 was submitted in 2023 and can be accessed here.
Mission Statement of Overton Brooks Research Corporation
Overton Brooks Research Corporation exists with a singular objective: to bolster and facilitate medical research activities of its members in conjunction with the Overton Brooks Veterans Affairs Medical Center. This organization plays a crucial role in supporting the medical research endeavors of its members, contributing to the advancement of medical knowledge and potential breakthroughs.
One of the primary initiatives undertaken by Overton Brooks Research Corporation is its involvement in the National Institutes of Health (NIH) study, All of Us. Led by Dr. Philip Haddad as the principal investigator, the program invites individuals from across the United States to contribute to building diverse health databases. At Overton Brooks Research Corporation, the goal is to enroll 40 individuals monthly. A crucial component of this project is a blood draw, which serves as a valuable resource for researchers.
The ultimate objective of All of Us is to expedite medical research breakthroughs. By amassing one of the largest biomedical databases, with over one million enrollees, researchers can gain access to an extensive pool of data. This data can help scientists better understand the connection between variables and diseases or treatments, potentially speeding up the process of making discoveries. While it may take years to decipher the intricate links between variables and diseases, the creation of such a comprehensive dataset could potentially accelerate this process, leading to advancements in medical research and potential treatments.
Shop smarter and support your favorite cause with the Give Freely browser extension. Save money with coupons and donate to charity with a single click. Download now!
Impact
October, 2024
Overton Brooks Research Corporation is conducting a significant phase 3 clinical trial evaluating pembrolizumab (MK-3475) in combination with concurrent chemoradiation therapy. This research aims to enhance treatment outcomes for patients by assessing the effectiveness of this combination therapy compared to standard concurrent chemoradiation therapy alone. By integrating olaparib (MK-7339) into the treatment protocol for some participants, the study seeks to explore potential advancements in cancer treatment options, providing valuable insights into the efficacy of combining immunotherapy and targeted therapy.
The outcomes of this research could lead to improved strategies for managing cancer, ultimately impacting patient care and survival rates, especially in Shreveport, LA, and beyond. Furthermore, the rigorous design of the randomized, double-blind, placebo-controlled format ensures that the findings will contribute to the broader scientific understanding of cancer therapies, potentially influencing future treatment guidelines and protocols.
This information is meant to be a general summary of Overton Brooks Research Corporation. Please take the time to review official sources before making any decisions based upon the content provided here.
Financials
This financial information is from Propublica.
Other financial information:
This information is from the most recently submitted tax form from this organization, which was in 2023.
- Investment Income: $36
- Program Service Revenue: $264,222
- Gross Receipts: $264,258
Assets and Liabilities:
- Total Assets: $122,431
- Total Liabilities: $0
- Net Assets: $122,431
Want to help this charity, for free? You can click here to learn more about Give Freely
Programs
Programs are reported by nonprofits in their tax forms and are normally their tax-exempt activities.
RESEARCH STUDIES
Revenue
$264,222
Organization Details
Founding Year
1991
Phone
(318) 990-5155Principal Officer
John T Gleason
Main Address
510 STONER AVE BLDG 33, SHREVEPORT, LA, 711014295
If you are a representative of Overton Brooks Research Corporation and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.